These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33436475)

  • 1. Study protocol: randomised controlled trial evaluating exercise therapy as a supplemental treatment strategy in early multiple sclerosis: the Early Multiple Sclerosis Exercise Study (EMSES).
    Riemenschneider M; Hvid LG; Ringgaard S; Nygaard MKE; Eskildsen SF; Petersen T; Stenager E; Dalgas U
    BMJ Open; 2021 Jan; 11(1):e043699. PubMed ID: 33436475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study protocol: effects of exercise booster sessions on preservation of exercise-induced adaptations in persons with multiple sclerosis, a multicentre randomised controlled trial-the MS BOOSTER trial.
    Taul-Madsen L; Hvid LG; Sellebjerg F; Christensen JR; Ratzer R; Sejbæk T; Svendsen KB; Papp V; Højsgaard Chow H; Lundbye-Jensen J; Dawes H; Dalgas U
    BMJ Open; 2024 Aug; 14(8):e085241. PubMed ID: 39153792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES).
    Riemenschneider M; Hvid LG; Ringgaard S; Nygaard MKE; Eskildsen SF; Gaemelke T; Magyari M; Jensen HB; Nielsen HH; Kant M; Falah M; Petersen T; Stenager E; Dalgas U
    Mult Scler; 2022 Sep; 28(10):1620-1629. PubMed ID: 35296183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial.
    De Keersmaecker AV; Van Doninck E; Popescu V; Willem L; Cambron M; Laureys G; D' Haeseleer M; Bjerke M; Roelant E; Lemmerling M; D'hooghe MB; Derdelinckx J; Reynders T; Willekens B
    Front Immunol; 2024; 15():1362629. PubMed ID: 38680485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amantadine and/or transcranial magnetic stimulation for fatigue associated with multiple sclerosis (FETEM): study protocol for a phase 3 randomised, double-blind, cross-over, controlled clinical trial.
    Matias-Guiu JA; González-Rosa J; Hernández MÁ; Martínez-Ginés ML; Portolés A; Pérez-Macías N; Benito-León J; Padrón I; Prieto J; Matias-Guiu J
    BMJ Open; 2024 Jan; 14(1):e078661. PubMed ID: 38176857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective effects of exercise in people with progressive multiple sclerosis (Exercise PRO-MS): study protocol of a phase II trial.
    Gravesteijn AS; Beckerman H; de Jong BA; Hulst HE; de Groot V
    BMC Neurol; 2020 May; 20(1):177. PubMed ID: 32393193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A self-management programme to reduce falls and improve safe mobility in people with secondary progressive MS: the BRiMS feasibility RCT.
    Gunn H; Andrade J; Paul L; Miller L; Creanor S; Stevens K; Green C; Ewings P; Barton A; Berrow M; Vickery J; Marshall B; Zajicek J; Freeman J
    Health Technol Assess; 2019 Jun; 23(27):1-166. PubMed ID: 31217069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protocol for an exploratory, randomised, single-blind clinical trial of aerobic exercise to promote remyelination in multiple sclerosis.
    Wooliscroft L; McCoy S; Hildebrand A; Rooney W; Oken BS; Spain RI; Kuehl KS; Bourdette D; Cameron M
    BMJ Open; 2023 Jan; 13(1):e061539. PubMed ID: 36596632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualised behaviour change strategies for physical activity in multiple sclerosis (IPAC-MS): protocol for a randomised controlled trial.
    Goulding FL; Evans CD; Knox KB; Lim HJ; Levin MC; Donkers SJ
    Trials; 2019 Dec; 20(1):664. PubMed ID: 31791380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finding the right balance with participation in exercise and sport for individuals with multiple sclerosis: protocol for a pre and post intervention feasibility study.
    Smith M; Williams G; Barker R
    BMJ Open; 2020 Mar; 10(3):e035378. PubMed ID: 32193273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design of a single-blind, randomised controlled trial of exercise training for managing learning and memory impairment in persons with multiple sclerosis.
    Sandroff BM; Motl RW; Bamman M; Cutter GR; Bolding M; Rinker JR; Wylie GR; Genova H; DeLuca J
    BMJ Open; 2018 Dec; 8(12):e023231. PubMed ID: 30552263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exercise Therapy in Early Multiple Sclerosis Improves Physical Function But Not Cognition: Secondary Analyses From a Randomized Controlled Trial.
    Riemenschneider M; Hvid LG; Petersen T; Stenager E; Dalgas U
    Neurorehabil Neural Repair; 2023 May; 37(5):288-297. PubMed ID: 36905131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translingual neurostimulation combined with physical therapy to improve walking and balance in multiple sclerosis (NeuroMSTraLS): Study protocol for a randomized controlled trial.
    Ploughman M; Melam GR; Buragadda S; Lohse KR; Clift F; Stefanelli M; Levin M; Donkers SJ
    Contemp Clin Trials; 2023 Apr; 127():107142. PubMed ID: 36878390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT.
    Lincoln NB; Bradshaw LE; Constantinescu CS; Day F; Drummond AE; Fitzsimmons D; Harris S; Montgomery AA; das Nair R
    Health Technol Assess; 2020 Jan; 24(4):1-182. PubMed ID: 31934845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nutrition and Exercise in Critical Illness Trial (NEXIS Trial): a protocol of a multicentred, randomised controlled trial of combined cycle ergometry and amino acid supplementation commenced early during critical illness.
    Heyland DK; Day A; Clarke GJ; Hough CT; Files DC; Mourtzakis M; Deutz N; Needham DM; Stapleton R
    BMJ Open; 2019 Jul; 9(7):e027893. PubMed ID: 31371287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of power training in older patients with multiple sclerosis on neurodegeneration, neuromuscular function, and physical function. A study protocol for the "power training in older multiple sclerosis patients (PoTOMS) randomized control trial.
    Gaemelke T; Laustsen C; Feys P; Folkestad L; Andersen MS; Jørgensen NR; Jørgensen ML; Jespersen SN; Ringgaard S; Eskildsen SF; Dalgas U; Hvid LG
    Contemp Clin Trials Commun; 2024 Apr; 38():101279. PubMed ID: 38444875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.